FY2026 Earnings Estimate for Neogen Issued By Zacks Research

Neogen Co. (NASDAQ:NEOG - Free Report) - Investment analysts at Zacks Research lowered their FY2026 EPS estimates for Neogen in a research note issued on Wednesday, June 4th. Zacks Research analyst R. Department now forecasts that the company will earn $0.38 per share for the year, down from their previous forecast of $0.39. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q4 2026 earnings at $0.09 EPS and FY2027 earnings at $0.43 EPS.

Neogen (NASDAQ:NEOG - Get Free Report) last announced its quarterly earnings results on Wednesday, April 9th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.02). The company had revenue of $221.00 million during the quarter, compared to analyst estimates of $225.27 million. Neogen had a negative net margin of 52.12% and a positive return on equity of 2.89%. Neogen's quarterly revenue was down 3.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.12 EPS.

Several other brokerages have also commented on NEOG. Piper Sandler decreased their price target on Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a research note on Tuesday, April 22nd. Guggenheim reduced their price objective on Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th.

Neogen Price Performance

NEOG stock traded up $0.31 during trading on Friday, hitting $5.52. The company had a trading volume of 5,322,034 shares, compared to its average volume of 3,196,212. The company has a fifty day moving average price of $5.84 and a two-hundred day moving average price of $9.35. The company has a current ratio of 3.77, a quick ratio of 2.46 and a debt-to-equity ratio of 0.33. The company has a market cap of $1.20 billion, a P/E ratio of -2.52 and a beta of 1.84. Neogen has a fifty-two week low of $3.87 and a fifty-two week high of $18.58.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NEOG. Connable Office Inc. grew its holdings in Neogen by 5.6% in the 4th quarter. Connable Office Inc. now owns 18,793 shares of the company's stock valued at $228,000 after buying an additional 1,000 shares in the last quarter. Covestor Ltd lifted its position in shares of Neogen by 41.4% during the 4th quarter. Covestor Ltd now owns 4,103 shares of the company's stock worth $50,000 after buying an additional 1,202 shares during the last quarter. Inspire Advisors LLC lifted its position in shares of Neogen by 10.1% during the 4th quarter. Inspire Advisors LLC now owns 14,226 shares of the company's stock worth $173,000 after buying an additional 1,304 shares during the last quarter. CHICAGO TRUST Co NA raised its position in Neogen by 19.1% in the first quarter. CHICAGO TRUST Co NA now owns 12,498 shares of the company's stock valued at $108,000 after purchasing an additional 2,000 shares during the last quarter. Finally, Ascent Group LLC raised its position in Neogen by 17.8% in the fourth quarter. Ascent Group LLC now owns 14,340 shares of the company's stock valued at $174,000 after purchasing an additional 2,165 shares during the last quarter. 96.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Neogen

In other news, Director Aashima Gupta purchased 16,000 shares of Neogen stock in a transaction dated Monday, May 12th. The shares were bought at an average cost of $6.25 per share, with a total value of $100,000.00. Following the completion of the transaction, the director now directly owns 21,917 shares in the company, valued at $136,981.25. This trade represents a 270.41% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO John Patrick Moylan bought 10,000 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The stock was purchased at an average cost of $5.07 per share, for a total transaction of $50,700.00. Following the transaction, the chief accounting officer now owns 10,000 shares in the company, valued at $50,700. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 83,500 shares of company stock valued at $431,525. 1.13% of the stock is currently owned by company insiders.

Neogen Company Profile

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.